How ACCURE Closed Racial Survival Gaps in Cancer — And How CMS PIN Codes Scale It
You’ve seen the survival gaps. You’ve felt the impact. And the question that follows is both urgent and fair:What exactly can you do about it — in your clinic, with…
Operationalizing Early Palliative Care: Systems, Codes, and Metrics for Oncology Success
- Post category:Pan Cancer/Supportive Oncology/Survivorship
- Reading time:5 mins read
You know palliative care isn’t an end-of-life intervention. It’s a proactive, evidence-based system that extends survival, preserves dose intensity, and minimizes avoidable treatment disruptions. So, here's the real question: How…
The Immunotherapy Clock Has Moved
- Post category:Breast Cancer/Genitourinary (Prostate, Bladder) System/Head & Neck Cancers/Pan Cancer/Respiratory (Lung, Bronchus) System/Supportive Oncology/Survivorship
- Reading time:3 mins read
Checkpoint inhibitors are no longer reserved for late-stage salvage. The clearest signal from recent meetings and trials is this: the greatest survival benefit may be increasingly found in neoadjuvant and perioperative settings. This…
Biomarkers: Are You Testing and Early Enough, Yet?
- Post category:Digestive (CRC, Stomach) System/Pan Cancer/Supportive Oncology/Survivorship
- Reading time:4 mins read
Coming off Colorectal Cancer Awareness Month, the conversation around rising cases, younger patients, and late-stage diagnoses is intensifying. NCCN has updated its guidance. New targeted options—including one approved April 8,…
The Fatigue We Still Don’t Treat Seriously Enough
- Post category:Pan Cancer/Supportive Oncology/Survivorship
- Reading time:4 mins read
We escalate for dyspnea. We act on chest pain. But fatigue - the kind that erodes function, adherence, and dignity - is still routinely noted, not treated. That’s no longer…
Time to Treat Exercise Like a Therapy?
- Post category:Digestive (CRC, Stomach) System/Supportive Oncology/Survivorship
- Reading time:4 mins read
How often are you asked, “Is there anything else I can do to keep my cancer from coming back?” For the first time, Phase III evidence says yes. The CHALLENGE trial (CCTG…
